IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v47y2024i8d10.1007_s40264-024-01431-7.html
   My bibliography  Save this article

Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database

Author

Listed:
  • Renato de Filippis

    (University Magna Graecia of Catanzaro)

  • John M. Kane

    (The Zucker Hillside Hospital, Psychiatry Research, Northwell Health
    Zucker School of Medicine at Northwell/Hofstra
    Feinstein Institute for Medical Research)

  • Elena Arzenton

    (University of Verona)

  • Ugo Moretti

    (University of Verona)

  • Emanuel Raschi

    (University of Bologna)

  • Gianluca Trifirò

    (University of Verona)

  • Corrado Barbui

    (University of Verona)

  • Pasquale De Fazio

    (University Magna Graecia of Catanzaro)

  • Chiara Gastaldon

    (University of Verona
    University of Bern)

  • Georgios Schoretsanitis

    (The Zucker Hillside Hospital, Psychiatry Research, Northwell Health
    Zucker School of Medicine at Northwell/Hofstra
    Hospital of Psychiatry, University of Zurich)

Abstract

Introduction Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is gaining attention in pharmacovigilance, but its association with antipsychotics, other than clozapine, is still unclear. Methods We conducted a case/non-case study with disproportionality analysis based on the World Health Organization (WHO) global spontaneous reporting database, VigiBase®. We analyzed individual case safety reports of DRESS syndrome related to antipsychotics compared to (1) all other medications in VigiBase®, (2) carbamazepine (a known positive control), and (3) within classes (typical/atypical) of antipsychotics. We calculated reporting odds ratio (ROR) and Bayesian information component (IC), with 95% confidence intervals (CIs). Disproportionate reporting was prioritized based on clinical importance, according to predefined criteria. Additionally, we compared characteristics of patients reporting with serious/non-serious reactions. Results A total of 1534 reports describing DRESS syndrome for 19 antipsychotics were identified. The ROR for antipsychotics as a class as compared to all other medications was 1.0 (95% CI 0.9–1.1). We found disproportionate reporting for clozapine (ROR 2.3, 95% CI 2.1–2.5; IC 1.2, 95% CI 1.1–1.3), cyamemazine (ROR 2.3, 95% CI 1.5–3.5; IC 1.2, 95% CI 0.5–1.7), and chlorpromazine (ROR 1.5, 95% CI 1.1–2.1; IC 0.6, 95% CI 0.1–1.0). We found 35.7% of cases with co-reported anticonvulsants, and 25% with multiple concurrent antipsychotics in serious compared to 8.6% in non-serious cases (p = 0.03). Fatal cases were 164 (10.7%). Conclusions Apart from the expected association with clozapine, chlorpromazine and cyamemazine (sharing an aromatic heteropolycyclic molecular structure) emerged with a higher-than-expected reporting of DRESS. Better knowledge of the antipsychotic-related DRESS syndrome should increase clinicians’ awareness leading to safer prescribing of antipsychotics.

Suggested Citation

  • Renato de Filippis & John M. Kane & Elena Arzenton & Ugo Moretti & Emanuel Raschi & Gianluca Trifirò & Corrado Barbui & Pasquale De Fazio & Chiara Gastaldon & Georgios Schoretsanitis, 2024. "Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database," Drug Safety, Springer, vol. 47(8), pages 745-757, August.
    • Handle: RePEc:spr:drugsa:v:47:y:2024:i:8:d:10.1007_s40264-024-01431-7
    DOI: 10.1007/s40264-024-01431-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-024-01431-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-024-01431-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:47:y:2024:i:8:d:10.1007_s40264-024-01431-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.